

SUPPORT FOR THE AMENDMENTS

Support for the amendments to Claims 8, 15 and 22 is found in original Claim 8.

No new matter will be added to this application by entry of this amendment.

Claims 1-30 are active.

RESPONSE TO THE RESTRICTION REQUIREMENT

The claims have been divided into Groups as follows:

- Group I: Claim(s) 1-3, 5-8, 10-22, drawn to factor X analogues in which Thr-Arg-Ile at the activation site is replaced, DNA encoding said analogs, and methods of making and using said analogues.
- Group II: Claim(s) 23-24, drawn to a method of treating coagulopathy utilizing said analogue.
- Group III: Claim(s) 4, 25-30, drawn to factor X analogues which can be obtained by a cleavage of factor X analogues wherein said factor X analogues are those recited in Group I, DNA encoding said analogues and methods of making and using said analogues.
- Group IV: Claim(s) 4, 25-30, drawn to factor X analogues which can be obtained by a cleavage of factor X analogue analogues, DNA encoding said analogues and methods of making and using said analogues.

In addition, if Group I or II is elected, an election of a specific SEQ ID NO: 31 is required as indicated:

- Election: A single sequence representing SEQ ID NO: 31, fully identifying all residues is required.

Applicants elect without traverse Group I, Claims 1-3, 5-8, 10-22, for examination.

As the single sequence representing SEQ ID NO: 31, Applicants elect the sequence Val-Pro-Arg-Ala-Val-Gly (SEQ ID NO: 9).

REMARKS/ARGUMENTS

Applicants respectfully note that Claim 9 was not included in any of the original Groups. Claim 10 depends from Claim 9 and therefore Claim 9 should be included in the elected Claims.

Moreover, Claims 23 and 24 describe a use of the factor X analogue described in Claims 1-3 and 5-22. Applicants respectfully note that the above identified application is the national stage of PCT/EP03/07793 and that 37 C.F.R. § 1.475(b) states in pertinent part:

“An international or a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:


(3) A product, a process specially adapted for the manufacture of the said product, and a use of said product; . . .”

Applicants respectfully note that Claims 23 and 24 indirectly depend from Claim 1 and according to 37 C.F.R. § 1.475(b) should therefore be examined with Claims 1-3 and 5-22.

Applicants respectfully submit that the above-identified application is now in condition for examination on the merits and early notice of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Jay E. Rowe Jr., Ph.D.

Registration No. 58,948

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 08/07)